REFERENCES
1. World Health Organization. Influenza (Seasonal). World Health
Organization.
2. Takashita E, Daniels RS, Fujisaki S, et al. Global update on the
susceptibilities of human influenza viruses to neuraminidase inhibitors
and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018.Antiviral Res . 2020;175(January).
doi:10.1016/j.antiviral.2020.104718
3. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance
among influenza A viruses isolated early during the 2005-2006 influenza
season in the United States. J Am Med Assoc . 2006;295(8):891-894.
doi:10.1001/jama.295.8.joc60020
4. Hurt AC. The epidemiology and spread of drug resistant human
influenza viruses. Curr Opin Virol . 2014;8:22-29.
doi:10.1016/j.coviro.2014.04.009
5. Hauge SH, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P.
Sales of oseltamivir in Norway prior to the emergence of oseltamivir
resistant influenza A(H1N1) viruses in 2007-08. Virol J .
2009;6:4-7. doi:10.1186/1743-422X-6-54
6. Butler J, Hooper KA, Petrie S, et al. Estimating the Fitness
Advantage Conferred by Permissive Neuraminidase Mutations in Recent
Oseltamivir-Resistant A(H1N1)pdm09 Influenza Viruses. PLoS
Pathog . 2014;10(4). doi:10.1371/journal.ppat.1004065
7. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for
uncomplicated influenza in adults and adolescents. N Engl J Med .
2018;379(10):913-923. doi:10.1056/NEJMoa1716197
8. Ison MG, Portsmouth S, Yoshida Y, et al. Baloxavir marboxil in
high-risk adolescent and adult outpatients with uncomplicated influenza.Lancet Infect Dis ., in press.
9. Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of
baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of
the influenza virus polymerase PA subunit. Antiviral Res .
2018;160(October):109-117. doi:10.1016/j.antiviral.2018.10.008
10. Omoto S, Speranzini V, Hashimoto T, et al. Characterization of
influenza virus variants induced by treatment with the endonuclease
inhibitor baloxavir marboxil. Sci Rep . 2018;8(1):1-15.
doi:10.1038/s41598-018-27890-4
11. Stevaert A, Dallocchio R, Dessi A, et al. Mutational Analysis of the
Binding Pockets of the Diketo Acid Inhibitor L-742,001 in the Influenza
Virus PA Endonuclease. J Virol . 2013;87(19):10524-10538.
doi:10.1128/jvi.00832-13
12. Pflug A, Lukarska M, Resa-infante P, Reich S, Cusack S. Structural
insights into RNA synthesis by the influenza virus
transcription-replication machine. Virus Res . 2017;234:103-117.
doi:10.1016/j.virusres.2017.01.013
13. Mishin VP, Patel MC, Chesnokov A, et al. Susceptibility of Influenza
A, B, C, and D Viruses to Baloxavir 1. 2019;25(10):1969-1972.
14. Peng Q, Liu Y, Peng R, et al. Structural insight into RNA synthesis
by influenza D polymerase. Nat Microbiol . 2019;4(10):1750-1759.
doi:10.1038/s41564-019-0487-5
15. Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-Emergent
Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact
on Clinical and Virologic Outcomes in Uncomplicated Influenza. J
Infect Dis . 2020;221(3):346-355. doi:10.1093/infdis/jiz244
16. Takashita E, Kawakami C, Ogawa R, et al. Influenza a(H3N2) virus
exhibiting reduced susceptibility to baloxavir due to a polymerase
acidic subunit I38T substitution detected from a hospitalised child
without prior baloxavir treatment, Japan, January 2019.Eurosurveillance . 2019;24(12):1-4.
doi:10.2807/1560-7917.ES.2019.24.12.1900170
17. Takashita E, Ichikawa M, Morita H, et al. Human-to-human
transmission of influenza A(H3N2) virus with reduced susceptibility to
baloxavir, Japan, February 2019. Emerg Infect Dis .
2019;25(11):2108-2111. doi:10.3201/eid2511.190757
18. Imai M, Yamashita M, Sakai-Tagawa Y, et al. Influenza A variants
with reduced susceptibility to baloxavir isolated from Japanese patients
are fit and transmit through respiratory droplets. Nat Microbiol .
2019:1-7. doi:10.1038/s41564-019-0609-0
19. Gubareva L V., Mishin VP, Patel MC, et al. Assessing baloxavir
susceptibility of influenza viruses circulating in the United States
during the 2016/17 and 2017/18 seasons. Eurosurveillance .
2019;24(3):9-13. doi:10.2807/1560-7917.ES.2019.24.3.1800666
20. Ince WL, Smith FB, O’Rear JJ, Thomson M. Treatment-emergent
influenza virus PA substitutions independent of those at I38 associated
with reduced baloxavir susceptibility and virus rebound in trials of
baloxavir marboxil. J Infect Dis . 2020;(1):1-5.
doi:10.1093/infdis/jiaa164
21. McAuley JL, Gilbertson BP, Trifkovic S, Brown LE, McKimm-Breschkin
JL. Influenza virus neuraminidase structure and functions. Front
Microbiol . 2019;10(JAN). doi:10.3389/fmicb.2019.00039
22. Goldhill DH, Te Velthuis AJW, Fletcher RA, et al. The mechanism of
resistance to favipiravir in influenza. Proc Natl Acad Sci U S A .
2018;115(45):11613-11618. doi:10.1073/pnas.1811345115
23. Watanabe A, Ishida T, Hirotsu N, et al. Baloxavir marboxil in
Japanese patients with seasonal influenza: Dose response and virus
type/subtype outcomes from a randomized phase 2 study. Antiviral
Res . 2019;163(January):75-81. doi:10.1016/j.antiviral.2019.01.012
24. Hirotsu N, Sakaguchi H, Sato C, et al. Baloxavir Marboxil in
Japanese Pediatric Patients With Influenza: Safety and Clinical and
Virologic Outcomes. Clin Infect Dis . 2019:1-11.
doi:10.1093/cid/ciz908
25. Chesnokov A, Patel MC, Mishin VP, et al. Replicative Fitness of
Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.J Infect Dis . 2020;221(3):367-371. doi:10.1093/infdis/jiz472
26. Sato M, Takashita E, Katayose M, et al. Detection of Variants With
Reduced Baloxavir Marboxil Susceptibility After Treatment of Children
With Influenza A During the 2018–2019 Influenza Season. J Infect
Dis . 2020;(Xx Xxxx):1-5. doi:10.1093/infdis/jiaa061
27. Ahmed AR. H1N1 with fatal viral septicemia in a normal child: A case
report. Respir Med Case Reports . 2020;30:101055.
doi:10.1016/j.rmcr.2020.101055